Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Breast cancer is a type of catastrophic disease, which is classified as high cost, high volume and high risk, causing the cost of disease to be very expensive. Based on data from the claim of Indonesian-Case Based Groups until the January 2016 pay month, cancer ranks second after the heart disease which requires the most medical expenses, which is Rp1.8 trillion. The purpose of this study was to find out the description of chemotherapy and find out how much the difference in real costs with INA-CBGs rates in patients with breast cancer chemotherapy hospitalized JKN participants in Ulin Banjarmasin Hospital. This research was a pharmacoeconomic analysis research with a hospital perspective on direct medical costs, and the data was taken retrospectively. The object of this study was the financial file of hospital inpatient services and medical records of JKN participants' breast cancer patients for the period of January-October 2017 in Ulin Banjarmasin Hospital. The samples were 259 episodes of care. Data analysis was carried out with one sample test to compare the average real cost with the INA-CBGs rate. The results showed the description of chemotherapy in breast cancer patients hospitalized participants with the National Health Insurance at Ulin Banjarmasin Hospital in January – October 2017 period was docetaxel 62.36%, cyclophosphamide 52.35% and epirubicin 40%. The magnitude of the difference between the real cost and the INA-CBGs package tariff was Rp662,143,091 (259 episodes of care). The average real cost of chemotherapy per episode of treatment at the level of severity I was Rp4,502,210, at the severity level II was Rp8,239,624, and at the severity level, III was Rp7,403,713.